Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

A novel method for direct measurement of complement convertases activity in human serum.

In English

Författare

  • Anna Blom
  • Elena B Volokhina
  • Viktor Fransson
  • Patrik Strömberg
  • Lotta Berghard
  • Margareta Viktorelius
  • Tom Eirik Mollnes
  • Margarita Lopez-Holmberg
  • Lambertus P van den Heuvel
  • Tim H Goodship
  • Kevin J Marchbank
  • Marcin Okroj
Visa allt

Summary, in English

Complement convertases are enzymatic complexes that play a central role in sustaining and amplification of the complement cascade. Impairment of complement function directly or indirectly leads to pathologic conditions including higher infection rate, kidney diseases, autoimmune- or neurodegenerative diseases and ischemia-reperfusion injury. An assay for direct measurement of activity of the convertases in patient sera is not available. Existing assays testing convertase function are based on purified complement components and thus, convertase formation occurs under non-physiological conditions. We designed a new assay, in which C5 blocking compounds enabled separation of the complement cascade into two phases: the first ending at the stage of C5 convertases and the second ending with membrane attack complex formation. Use of rabbit erythrocytes or antibody-sensitized sheep erythrocytes as the platforms for convertase formation enabled easy readout based on measurement of hemolysis. Thus, properties of patient sera could be studied directly regarding convertase activity and membrane attack complex formation. Another advantage of this assay was the possibility to screen for host factors such as C3 nephritic factor and other anti-complement autoantibodies, or gain-of-function mutations, which prolong half-live of complement convertases. Herein, we present proof of concept, detailed description and validation of this novel assay.

Publiceringsår

2014

Språk

Engelska

Sidor

142-153

Publikation/Tidskrift/Serie

Clinical and Experimental Immunology

Volym

178

Issue

1

Dokumenttyp

Artikel i tidskrift

Förlag

British Society for Immunology

Ämne

  • Immunology in the medical area

Status

Published

Forskningsgrupp

  • Protein Chemistry, Malmö

ISBN/ISSN/Övrigt

  • ISSN: 0009-9104